trial

Nicotinic Receptors and Schizophrenia

NCTId NCT01400477
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 97 (actual)
Sponsored by University of Colorado, Denver
Primary completion 2015-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
97 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-07
Primary completion
2015-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
DMXB-A-SR

Sponsors

University of Colorado, DenverLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Robert Freedman, MDPrincipal Investigator

Sites

2 total
Aurora, United StatesAurora, United States

Linked catalysts

1
Nicotinic Receptors and Schizophrenia — primary completion2015-06

Facts & assertions

4 sourced
Enrollment
97
Phase
PHASE2
Primary Completion Date
2015-06
Status
COMPLETED
relationships
The graph out of here
drug
DMXB-A-SR
drug
lead_sponsor
University of Colorado, Denver
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Smoking
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Robert Freedman, MD
person